Related Experiment Videos

Endothelial derived vasoactive factors and leukocyte derived inflammatory mediators in subjects with asymptomatic

I Anwaar1, A Gottsäter, B Hedblad

  • 1Department of Medicine, Lund University, University Hospital, Malmö, Sweden.

Angiology
|December 17, 1998
PubMed

Insights

Leukocyte inflammatory mediators may inhibit platelet activation in atherosclerosis. This study found relationships between inflammatory markers and platelet cyclic nucleotides, suggesting a feedback mechanism to control platelet aggregation.

Area of Science:

  • Cardiovascular Biology
  • Inflammation Research
  • Platelet Physiology

Background:

  • Asymptomatic atherosclerosis involves complex interactions between endothelial function and inflammatory processes.
  • Leukocyte-derived inflammatory mediators play a role in cardiovascular disease progression.
  • Platelet activation is a critical component of the atherosclerotic inflammatory cascade.

Purpose of the Study:

  • To investigate the relationship between endothelial function markers and leukocyte inflammatory mediators in asymptomatic atherosclerosis.
  • To explore the association between intraplatelet cyclic nucleotides (cGMP, cAMP) and inflammatory markers.

Main Methods:

  • Measured intraplatelet cyclic 3',5'-guanosine monophosphate (cGMP) and cyclic 3',5'-adenosine monophosphate (cAMP) in 197 subjects.
  • Assessed plasma endothelin-1 (ET-1) and neopterin levels.
  • Quantified neutrophil protease 4 (NP4), tumor necrosis factor (TNFmu), soluble tumor necrosis factor receptor-1 (sTNFR-1), and neutrophil gelatinase-associated lipocalin (NGAL) in a subset of subjects.

Main Results:

  • A negative correlation was observed between intraplatelet cyclic guanosine monophosphate (cGMP) and plasma endothelin-1 (ET-1).
  • Plasma neopterin and NP4 showed a positive correlation with intraplatelet cGMP.
  • Intraplatelet cyclic adenosine monophosphate (cAMP) correlated positively with plasma TNFmu and sTNFR-1.

Conclusions:

  • The findings suggest a potential anti-aggregating effect of leukocytes on platelets.
  • This interaction may represent a negative feedback mechanism to modulate platelet activation in atherosclerosis.
  • Understanding these relationships could offer insights into therapeutic strategies for atherosclerotic inflammation.

Related Concept Videos